To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: EFNS CONGRESS: Zyprexa Reduces Symptoms In Alzheimer's Patients URL: http://www.pslgroup.com/dg/B0BF6.htm Doctor's Guide September 22, 1998
SEVILLE, SPAIN -- Sept. 22, 1998 -- Study results show that Eli Lilly & Co.'s Zyprexa® (olanzapine) is able to improve psychosis and behavioural disturbances in patients with Alzheimer's disease. The study results were presented at the third congress of the European Federation of Neurological Societies. Zyprexa significantly reduced agitation, delusions and hallucinations compared to placebo, without the adverse side-effect profile associated with other antipsychotic agents. The drug is currently licensed for the management of schizophrenia and related psychotic disorders. Debilitating psychosis and behavioural disturbances are often associated with Alzheimer's and have a substantial impact on quality of life for both patients and their caregivers. Approximately half of patients seen in outpatients clinics and three quarters of those in nursing homes suffer from significant behavioural disturbances and the incidence of psychotic symptoms can be as high as 73 percent, with patients experiencing delusions, paranoia and hallucinations, the researchers explained. The study was a multicentre, randomised, double-blind, placebo-controlled trial, which examined the effects of Zyprexa on psychosis and behavioural disturbances in 206 nursing home patients with moderate to severe Alzheimer's over a six-week period. The results show that treatment with the drug is significantly better than treatment with placebo and the response rate of the Zyprexa 5 mg treatment group is nearly twice that of the placebo group. Related Links: Zyprexa, Eli Lilly & Co. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.